EMORY UNIVERSITY

A 25% weight loss among obese people could save up to $5,442 annually in health care costs, often achieved by GLP-1 users. The study, led by Kenneth Thorpe, suggests that improving access to weight-loss medications could reduce U.S. obesity-related health care spending.

The MOVe-NOW study will test a new LAGEVRIO formulation with smaller tablets, aiming to prevent severe COVID-19 outcomes. LAGEVRIO is authorized in several countries, including the U.S., for treating certain COVID-19 cases. The trial includes concomitant remdesivir use and evaluates efficacy, safety, and long-term COVID-19 effects.

USC Viterbi engineers developed an ultrasound-enhanced CRISPR toolkit for precise gene editing, demonstrating its efficacy in cancer immunotherapy by targeting tumor cells in mice, resulting in tumor clearance.

CVI visuospatial deficits involve differential recruitment of dorsal and ventral visual streams, with ventral stream showing greater activation in CVI patients, suggesting a complex clinical profile.

Dr. Jacqueline Brown discussed emerging perioperative systemic therapies for muscle invasive bladder cancer at the 2024 SUO annual meeting, highlighting the VESPER trial showing dose dense MVAC improved survival over gemcitabine + cisplatin, and the CheckMate 274 trial demonstrating adjuvant nivolumab's efficacy. Ongoing trials like NIAGARA and ENERGIZE explore chemo-immunotherapy combinations, while novel agents such as enfortumab vedotin and sacituzumab govitecan show promise in the perioperative setting.

USC engineers improved CRISPR with focused ultrasound, enabling precise gene editing and enhancing cancer immunotherapy in mouse studies.

Dr. Lei Zhu, Chief Operating Officer of MIGRA Therapeutics LLC and Assistant Professor at Emory University, has been included in Marquis Who's Who for his significant contributions to cancer research and innovative drug delivery approaches.

Platelets, crucial for blood clotting, face classification debates but remain lifesavers. Current platelet function assessment methods are inadequate, prompting new technologies focusing on force measurement. Innovations like Stasys Medical Corporation's platform and Mechano-Cas12a Assisted Tension Sensor (MCATS) aim to provide more precise, less invasive diagnostics, potentially revolutionizing trauma and surgical care.

The 'Nuclear Imaging Equipment Pipeline Report, 2024 Update' provides comprehensive details on pipeline products, clinical trials, and key companies involved in nuclear imaging equipment development, aiding strategic R&D, market entry, and mergers and acquisitions.

A twice-yearly injection of Lenacapavir offers a 96% reduced risk of HIV infection, significantly more effective than daily oral PrEP like Truvada®, according to a Gilead-funded clinical trial. The study, published in the New England Journal of Medicine, highlights the challenges of adherence to daily oral PrEP and underscores the need for more options, especially for populations disproportionately impacted by HIV.